Literature DB >> 2273388

Theiler's murine encephalomyelitis virus-binding activity on neural and non-neural cell lines and tissues.

N Rubio1, C De Felipe, C Torres.   

Abstract

Three categories of cell lines are described with respect to their activity in binding Theiler's murine encephalomyelitis virus (TMEV). High, medium and low densities of viral receptors can be detected on cell lines from different species and origins by using an immunological binding assay. Nevertheless, TMEV acts as a fastidious virus that only infects a few cell types productively. No correlation between virion binding and degree of permissiveness to infection could be detected. The presence of viral receptors in both susceptible and resistant strains of mice seemed to have a widespread tissue distribution, the thymus being an exception. When primary cerebral cultures, enriched in neurons, astrocytes or oligodendrocytes, were checked in the immunological assay, a higher density of viral receptors was detected in the neuronal population. The number of virus-binding sites in the BHK-21 cell line is reported here to be 5 x 10(3) per cell; approximately 15 x 10(3) and 2.5 x 10(3) are the estimates of binding sites per cultured neuron and macroglial cell, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2273388     DOI: 10.1099/0022-1317-71-12-2867

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Adenovirus vector-directed expression of the neurotrophin-3 receptor (TrkC) in mouse astrocytes.

Authors:  N Rubio; J Abad-Rodriguez
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

2.  Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection.

Authors:  Mary W Meagher; Robin R Johnson; Erin E Young; Elisabeth G Vichaya; Shannon Lunt; Elizabeth A Hardin; Marilyn A Connor; C Jane R Welsh
Journal:  Brain Behav Immun       Date:  2007-06-25       Impact factor: 7.217

3.  Interferon-gamma induces the expression of immediate early genes c-fos and c-jun in astrocytes.

Authors:  N Rubio
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

4.  Theiler's murine encephalomyelitis virus induces tumour necrosis factor-alpha in murine astrocyte cell cultures.

Authors:  A Sierra; N Rubio
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

5.  Absence of internal ribosome entry site-mediated tissue specificity in the translation of a bicistronic transgene.

Authors:  C Shaw-Jackson; T Michiels
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Mutation in loop I of VP1 of Theiler's virus delays viral RNA release into cells and enhances antibody-mediated neutralization: a mechanism for the failure of persistence by the mutant virus.

Authors:  Ingeborg J McCright; Ikuo Tsunoda; Jane E Libbey; Robert S Fujinami
Journal:  J Neurovirol       Date:  2002-04       Impact factor: 2.643

7.  Interleukin-6 protects anterior horn neurons from lethal virus-induced injury.

Authors:  Kevin D Pavelko; Charles L Howe; Kristen M Drescher; Jeff D Gamez; Aaron J Johnson; Tao Wei; Richard M Ransohoff; Moses Rodriguez
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

8.  Demonstration of the presence of an interleukin-1 receptor on the surface of murine astrocytes and its regulation by cytokines and Theiler's virus.

Authors:  N Rubio
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

9.  Response of Mammalian Macrophages to Challenge with the Chlorovirus Acanthocystis turfacea Chlorella Virus 1.

Authors:  Thomas M Petro; Irina V Agarkova; You Zhou; Robert H Yolken; James L Van Etten; David D Dunigan
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

10.  Induction of cytopathogenicity in human glioblastoma cells by chikungunya virus.

Authors:  Rachy Abraham; Prashant Mudaliar; Aiswaria Padmanabhan; Easwaran Sreekumar
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.